Business Standard

Sinopharm, J&J, Sputnik vaccines are weaker against Omicron, says report

The study also found that the lowest reduction in protective antibodies come from a combination of prior infection and two doses of Pfizer Inc.'s mRNA shots

Covid vaccine, covid-19
Premium

BloombergBS Web Team
Covid-19 shots made by China’s state-owned Sinopharm and Johnson & Johnson, as well as the Sputnik vaccine developed by Russia, were found to produce little or no antibodies against omicron in a study, as evidence of the new variant’s vaccine-evading abilities mount. 

Researchers at the University of Washington and Swiss drugmaker Humabs Biomed SA analyzed the efficacy of six vaccines against the highly-infectious and most-mutated Covid variant. Only three out of 13 people who has taken both doses of Sinopharm’s shot showed neutralizing antibodies against omicron. For J&J, this metric dropped to one out of 12 samples. None of the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in